Compare Bristol-Myers Squibb Co (BMY) vs GoPro Inc (GPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs GoPro Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.53 (market cap $116.30B), while GoPro Inc trades at $0.69 (market cap $120.72M). The key difference: Bristol-Myers Squibb Co is far larger — about 963.4× GoPro Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while GoPro Inc pays none. Which is the better fit depends on your goals.
| BMY | GPRO | |
|---|---|---|
Market Cap | $116.30B | $120.72M |
Sector | Health | Technology |
52-Week High | $62.37 | $2.88 |
52-Week Low | $42.60 | $0.64 |
Enterprise Value | $152.24B | $168.66M |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
GoPro (GPRO) trades at $0.711, down 6.79% on the day, reflecting persistent operational challenges and negative investor sentiment. The stock exhibits a bearish technical outlook with consecutive earnings misses, declining revenue from $1.1B in 2022 to $652M in 2025, and negative net income margins. Recent news highlights a strategic review for potential sale or merger amid financial distress, including a $20M financing injection from CEO Nicholas Woodman in July 2026 to bolster liquidity.
The investment outlook remains highly speculative, with opportunities tied to a potential strategic transaction offering upside, but severe risks include going-concern warnings, cash burn, and competitive pressures. Analyst consensus is cautious, with only 21% buy ratings, emphasizing the binary nature of outcomes based on the company's ability to secure a lifeline or execute a turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →
